Generalized myasthenia gravis (gMG) affects most patients through a handful of well-characterized neuromuscular junction ...

Opens in a new tab or window Generalized myasthenia gravis (gMG) affects most patients ... to reduce gMG exacerbations by targeting key mechanisms of disease pathogenesis," said John Morren ...

The present study does not shed further light on the mechanism either of myasthenia gravis or of the influence of the thyroid gland upon it. A case of a surgically athyreotic patient with ...

UCB emerged as a major biopharmaceutical player in the 1990s with the development of blockbuster drugs Zyrtec and Keppra. Throughout the 1990s and early 2000s, UCB transformed from a hybrid ...

Innovative platform trial revolutionizes ALS research by testing multiple treatments simultaneously, offering new hope ...

TEVIMBRA is a uniquely designed humanized immunoglobulin G4 (IgG4) anti-programmed cell death protein 1 (PD-1) monoclonal antibody with high affinity and binding specificity against PD-1. It is ...

With 2 new self-administration methods, patients living with generalized myasthenia gravis can be more empowered ... the first new treatment with a new mechanism of action in decades.

The funds will be used to support the advancement of the Chicago biotech’s myasthenia gravis (MG ... weight compounds targeting the underlying mechanisms of mucus congestion.

Myasthenia gravis (MG) is a acquired autoimmune disease mediated by ... Further in-depth research is needed to elucidate the specific pathophysiological mechanisms. Following HSCT, both patients ...